- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
- News News
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis in America Medical Cannabis Access for Pain Treatment
- Join Join
WASHINGTON, DC -- Today, the DC Council had a First Reading vote on the Medical Marijuana Omnibus Amendment Act of 2016 (B21-210), which would address a number of issues currently hampering the District’s Medical Marijuana Program (MMP). The bill will create lab testing, allow reciprocity, and remove the cultivation center plant count limit for the MMP.
“The original DC medical cannabis law passed by the Council did not authorize the Department of Health to license independent testing laboratories to ensure product safety,” said Steph Sherer, executive director of Americans for Safe Access. “This bill will allow patients to accurately know how much THC and other cannabinoids are in medical cannabis products and that they are free of contaminates; giving them greater confidence in the safety and reliability of their medicine.”
Additionally, the Council voted in favor an amendment that will lift the rule the only allows District patients to shop at one designated dispensary. The provision has long been cited by patients as one of their biggest frustrations with the program. Under the current law, if the patient’s designated dispensary runs out or does not stock a particular medical cannabis product, the patient could not shop at any of the other DC dispensaries to obtain the medicine that works best for them. By lifting the requirement, DC patients will have access to all of the medical cannabis products sold in the five licensed dispensaries in the District."
“Lifting the single dispensary designation requirement is a tremendous benefit for DC medical cannabis patients,” said Mike Liszewski, government affairs director at Americans for Safe Access. “Not only will this amendment increase patient choice in the District, but the increased competition should result in lower prices for patients.”
In addition to creating lab testing, reciprocity, and removal of the plant count limit, the bill will also allow District medical cannabis businesses to move their facilities within their Council Ward, enable ownership transfers, and grants nurses the right to issue medical cannabis recommendations. The nurse provision is subject to limitation by the Board of Nursing and Department of Health.
The Council will vote again on the Medical Marijuana Omnibus Amendment Act in a few weeks at Second Reading. If approved by the Council at Second Reading, the bill will go to the mayor’s desk for signature, then must pass a 30-day Congressional waiting period before it goes into effect.
More information: B21-0210 - Medical Marijuana Reciprocity Amendment Act
CONTACT: Anna Zuccaro |914-523-9145 | [email protected]